Leslie M Thompson

List of Publications by Year in Descending Order

24 papers	3,050 citations	16 h-index	44 g-index
44 ext. papers	3,639 ext. citations	12.9 avg, IF	3.94 L-index

#	Paper	IF	Citations
24	Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines.. *Nature Neuroscience*, **2022**, 25, 226-237	25.5	6
23	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. *IScience*, **2021**, 24, 103221	6.1	5
22	Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization. *Journal of Clinical Investigation*, **2021**, 131,	15.9	7
21	Cell Therapy for Huntington's Disease: Learning from Failure. *Movement Disorders*, **2021**, 36, 787-788	7	1
20	Calcium Dynamics in Astrocytes During Cell Injury. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 912	5.8	6
19	Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription. *ELife*, **2019**, 8,	8.9	45
18	Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice. *Stem Cell Reports*, **2018**, 10, 58-72	8	57
17	Fractionation for Resolution of Soluble and Insoluble Huntingtin Species. *Journal of Visualized Experiments*, **2018**,	1.6	6
16	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron*, **2018**, 97, 1268-1283.e6	13.9	296
15	The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin. *Neurobiology of Disease*, **2018**, 109, 127-136	7.5	15
14	Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier. *Cell Stem Cell*, **2017**, 20, 831-843.e5	18	130
13	Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits. *Cell Reports*, **2017**, 19, 1365-1377	10.6	143
12	KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4676-E4685	11.5	65
11	A Comparison of mRNA Sequencing with Random Primed and 3′-Directed Libraries. *Scientific Reports*, **2017**, 7, 14626	4.9	27
10	SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models. *Cell Chemical Biology*, **2016**, 23, 849-861	8.2	54
9	PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. *Neuron*, **2016**, 90, 507-20	13.9	45
8	TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E5655-64	11.5	53

List of Publications

7	Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. *Neuron*, **2015**, 85, 303-15	13.9	115
6	Potential function for the Huntingtin protein as a scaffold for selective autophagy. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 16889-94	11.5	183
5	Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. *Journal of Huntington's Disease*, **2014**, 3, 333-41	1.9	13
4	A transgenic minipig model of Huntington's Disease. *Journal of Huntington's Disease*, **2013**, 2, 47-68	1.9	70
3	Identifying polyglutamine protein species in situ that best predict neurodegeneration. *Nature Chemical Biology*, **2011**, 7, 925-34	11.7	152
2	Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. *Nature*, **2001**, 413, 739-43	50.4	1028
1	Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. *Nature Genetics*, **1995**, 9, 321-8	36.3	524